# Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease

> **NCT01570764** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 40 (actual)

## Conditions studied

- Systemic Sclerosis
- Scleroderma
- Interstitial Lung Disease
- Lung Fibrosis

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01570764
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-14
- **Primary completion:** 2018-02-22
- **Final completion:** 2018-02-22
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-09-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01570764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01570764, "Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01570764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*